Biotech Values

[DewDiligence]

>…[OXGN] topical administration does not seem sufficient as first line treatment but their idea of a single intravitreal injection followed by maintenance therapy seems to me a cleaver compromise for minimizing the potential side-effects.<

I think periodic intravitreal boosters will probably be needed even if daily eye drops are used for maintenance; however, the interval between injections may be able to be lengthened to, say, 6-8 months, which would be a huge competitive advantage relative to a monthly-injection regimen.